Modality
Gene Editing
MOA
PLK4i
Target
WEE1
Pathway
T-cell
RA
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
~Nov 2018
→ ~Feb 2020
NDA/BLA
May 2020
→ Feb 2029
NDA/BLACurrent
NCT07521277
1,704 pts·RA
2020-05→2029-02·Active
1,704 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-02-182.9y awayPh3 Readout· RA
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
NDA/BLA
Active
Catalysts
Ph3 Readout
2029-02-18 · 2.9y away
RA
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07521277 | NDA/BLA | RA | Active | 1704 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Bemavorutinib | Acadia Pharma | Phase 1/2 | WEE1 | |
| Talazumab | Zealand Pharma | Phase 1/2 | WEE1 | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | GPRC5D | |
| CSL-7919 | CSL Limited | Preclinical | BTK |